A Mazumder

3.1k total citations · 1 hit paper
17 papers, 2.4k citations indexed

About

A Mazumder is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, A Mazumder has authored 17 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 8 papers in Immunology and 5 papers in Oncology. Recurrent topics in A Mazumder's work include Immunotherapy and Immune Responses (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and T-cell and B-cell Immunology (4 papers). A Mazumder is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and T-cell and B-cell Immunology (4 papers). A Mazumder collaborates with scholars based in United States, Australia and Italy. A Mazumder's co-authors include Elizabeth A. Grimm, Steven A. Rosenberg, SA Rosenberg, J Y Djeu, David J. Wilson, R Agah, Mariella C. Tefft, Andrew L. Gilman, Brenda J. Berberian and Timothy J. Eberlein and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Immunology and JNCI Journal of the National Cancer Institute.

In The Last Decade

A Mazumder

17 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 1.8k citations Elizabeth A. Grimm, A Mazumder et al. The Journal of Experimental Medicine profile →

Peers

A Mazumder

IMMUN

ONCOL

RNMI

HEMAT

Richard D. Garman United States

D Y Mochizuki Canada

D E Kern United States

Tomoyuki Tagami Japan

R Mertelsmann Germany

Leslie M. McEvoy United States

Syamal K. Datta United States

R M O'Hara United States

F W Ruscetti United States

Kevin C. Conlon United States

Richard D. Garman United States

A Mazumder

1.3k ×0.7

IMMUN

380 ×0.4

ONCOL

403 ×1.2

413 ×1.4

RNMI

139 ×0.5

HEMAT

Citations per year, relative to A Mazumder A Mazumder (= 1×) peers Richard D. Garman

Countries citing papers authored by A Mazumder

Since Specialization

Citations

This map shows the geographic impact of A Mazumder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Mazumder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Mazumder more than expected).

Fields of papers citing papers by A Mazumder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Mazumder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Mazumder. The network helps show where A Mazumder may publish in the future.

Co-authorship network of co-authors of A Mazumder

This figure shows the co-authorship network connecting the top 25 collaborators of A Mazumder. A scholar is included among the top collaborators of A Mazumder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Mazumder. A Mazumder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Richardson, Paul G., Albert Oriol, Alessandra Larocca, et al.. (2019). S1605 HORIZON (OP‐106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM). HemaSphere. 3(S1). 739–739. 1 indexed citations

Gehan, E. A., et al.. (1999). Immunotherapy with interleukin-2 and α-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplantation. 23(7). 667–673. 23 indexed citations

Mazumder, A, et al.. (1997). Suppression of progenitor cell growth by vancomycin following autologous stem cell transplantation. Bone Marrow Transplantation. 19(10). 1029–1032. 7 indexed citations

Posey, James, et al.. (1997). Pilot trial of MDX-H210 and GM-CSF for patients with advanced erbB-2 positive malignancies. European Journal of Cancer. 33. S53–S53. 1 indexed citations

Mazumder, A. (1997). Experimental evidence of interleukin-2 activity in bone marrow transplantation.. PubMed. 3 Suppl 1. S37–42. 7 indexed citations

Verma, Udit, et al.. (1996). Immunomodulation following chemotherapy. Breast Cancer Research and Treatment. 38(1). 41–48. 2 indexed citations

Gilman, Andrew L., et al.. (1996). The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease.. PubMed. 17(6). 1069–75. 28 indexed citations

Meehan, Kenneth R., et al.. (1996). Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2.. PubMed. 6(1). 28–32. 11 indexed citations

Brown, Emily E., et al.. (1995). Prevention of acute graft-versus-host disease by treatment with a novel immunosuppressant. Cholera toxin B subunit.. The Journal of Immunology. 154(7). 3611–3617. 9 indexed citations

10.

Gray, DF, et al.. (1992). The acute phase response in autologous bone marrow transplantation.. PubMed. 23(3-4). 175–93. 9 indexed citations

11.

Agah, R, et al.. (1990). A novel approach to purging of leukemia by activation of bone marrow with interleukin 2.. PubMed. 6(3). 193–8. 24 indexed citations

12.

Watkins, Kristy, et al.. (1990). Hemolytic anemia in a cancer patient treated with recombinant interferon-gamma.. PubMed. 9(2). 256–9. 4 indexed citations

13.

Agah, R, et al.. (1989). Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation.. The Journal of Immunology. 143(9). 3093–3099. 38 indexed citations

14.

Mazumder, A, et al.. (1983). Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. The Journal of Experimental Medicine. 157(3). 884–897. 401 indexed citations

15.

Grimm, Elizabeth A., et al.. (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.. The Journal of Experimental Medicine. 155(6). 1823–1841. 1848 indexed citations breakdown →

16.

Rosenberg, Steven A., Timothy J. Eberlein, Elizabeth A. Grimm, et al.. (1982). Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.. PubMed. 92(2). 328–36. 17 indexed citations

17.

Mazumder, A, et al.. (1978). DNA Synthesis and Thymidine Kinase Activity of Rat Colon Epithelial Cells Fractionated by Discontinuous Ficoll Gradient: Brief Communication 2. JNCI Journal of the National Cancer Institute. 60(4). 915–918. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact